evipedia.ai
← Back

Tetradecylthioacetic Acid for Health & Longevity

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: TTA, Tetradecyl Thioacetic Acid, 2-(Tetradecylthio)acetic Acid, (Tetradecylthio)acetic Acid, (Tetradecylsulfanyl)acetic Acid, 1-(Carboxymethylthio)tetradecane, CMTTD, CMTD

Motivation

Tetradecylthioacetic acid (TTA) is a lab-made fatty acid with a sulfur atom placed near one end of its carbon chain. That small change means the body cannot burn it for fuel, yet it switches on the cell’s own fat-burning machinery, mainly in the liver. It draws interest from people pursuing a longer healthy life because blood fats, body fat and chronic low-grade inflammation are central drivers of heart disease and metabolic decline.

Norwegian university researchers have studied the compound for more than three decades, mostly in rats and mice, where it lowered blood fats, prevented diet-induced weight gain and calmed inflammation. Only a handful of short human studies followed. The compound was never approved as a medicine, yet it is sold online as a research chemical and fat-loss supplement.

This review examines what the human and animal evidence shows about the benefits and risks of taking the compound, how it has been dosed, how its effects can be tracked, and where the knowledge gaps lie for health-focused adults weighing its use.

Benefits - Risks - Protocol - Conclusion

This section lists narrative reviews that explain how TTA works and where it sits among related fat-metabolism drugs.

  • Metabolic effects of thia fatty acids - Berge et al., 2002

    A review by the Bergen group that developed TTA, whose lead scientists have been reported as shareholders in its developer Thia Medica; it summarizes effects on mitochondria, fat burning, insulin sensitivity and inflammation.

  • Thia fatty acids, metabolism and metabolic effects - Skrede et al., 1997

    An Oslo biochemistry review explaining why 3-thia fatty acids such as TTA cannot be burned as fuel, how the body clears them, and how they boost liver fat-burning enzymes.

  • Dual acting and pan-PPAR activators as potential anti-diabetic therapies - Heald & Cawthorne, 2011

    Places TTA among drugs that switch on several PPARs (peroxisome proliferator-activated receptors, fat-sensing gene switches) at once, and explains why related agents failed over weight gain, fluid retention, heart events and rodent tumors.

Only three items are listed: TTA is a niche research compound, nearly all other qualifying material is primary animal research from the same Bergen group, and adding it would duplicate that source or pad the list with marginally relevant content. No content on TTA was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; none of these platforms appears to have covered the compound.

Grokipedia

  • Tetradecylthioacetic acid

    An encyclopedia-style entry covering TTA’s chemistry, synthesis, biological mechanisms, physiological effects and research applications, useful as a quick orientation before the primary literature.

Examine

  • Tetradecyl Thioacetic Acid

    Describes TTA as a PPAR-alpha activator, notes its common pairing with oleoylethanolamide for fat loss, and cites a 1 g daily dose; its “omega-3” label for TTA is chemically inaccurate.

ConsumerLab

No ConsumerLab article on Tetradecylthioacetic Acid was found.

Systematic Reviews

No systematic reviews or meta-analyses for Tetradecylthioacetic Acid were found on PubMed as of 26 September 2026.

Neither the claimed benefits nor the principal risks are therefore represented by a systematic review or meta-analysis.

Mechanism of Action

TTA resembles a 17-carbon saturated fatty acid in which sulfur replaces the third carbon from the acid end. This blocks β-oxidation (the stepwise burning of fatty acids inside mitochondria, the cell’s power plants), so TTA yields no energy itself but strongly speeds the burning of ordinary fats.

  • Receptor activation: TTA activates all three PPAR subtypes, ranked PPARα > PPARδ > PPARγ in rodents (Madsen et al., 2002); in human liver and muscle cells PPARα and PPARδ dominate (Løvås et al., 2009). PPARα mainly drives liver fat burning, PPARδ muscle fat burning, and PPARγ fat storage.
  • Liver fat drainage: activation raises CPT-I (carnitine palmitoyltransferase I, the gate admitting fats into mitochondria), mitochondrial numbers and ketone (fat-derived fuel) production, pulling fatty acids out of blood and fat tissue (review by Berge et al., 2005).
  • Receptor-independent actions: in human blood-vessel cells TTA dampened inflammation without activating PPARα target genes (Dyrøy et al., 2005).
  • Competing view: the same extra heart fat burning lowered pumping efficiency in healthy mice (Hafstad et al., 2009) yet protected diabetic hearts (Khalid et al., 2011).
  • Pharmacology: oral absorption starts after a 1.5-hour lag, peaking at 2.5–4.5 hours; terminal half-life was not reported (Pettersen et al., 2008). TTA accumulates in membrane fats, especially in the heart, and is cleared by CYP4A-type enzymes (liver enzymes that oxidize the far end of fatty acids), sulfur oxidation and shortening in peroxisomes (small compartments that break down fats) to urinary acids (review by Skrede et al., 1997).

Historical Context & Evolution

TTA did not begin as a medicine. In the 1980s and early 1990s, biochemists at the University of Oslo made 3-thia fatty acids as research probes: because they cannot be burned, they let scientists trace how cells handle fats (review by Skrede et al., 1997). Rolf Berge’s Lipid Research Group at the University of Bergen then found that TTA multiplied liver peroxisomes in rats, much like fibrates (prescription triglyceride-lowering drugs) (Aarsland & Berge, 1991), and lowered blood triglycerides and cholesterol (Asiedu et al., 1996).

From the 1990s to the 2010s, rodent work reported prevention of diet-induced obesity and insulin resistance (Madsen et al., 2002), lower blood pressure (Gudbrandsen et al., 2006), less artery plaque and reduced inflammation (Vik et al., 2013). The Bergen group framed these results as a “liver fat drainage” model, which made TTA attractive for metabolic health; it reached the sports-supplement market as a fat-loss agent and was tested as a feed additive in farmed salmon (Alne et al., 2009).

Human testing stayed small: four short studies between 2004 and 2011 in people with HIV (human immunodeficiency virus), type 2 diabetes, psoriasis (an inflammatory skin disease) and healthy volunteers. The developer, Thia Medica AS, has not published large trials, and no regulator has approved TTA. Opinion has shifted less from new TTA data than from broader caution about PPAR-activating drugs after the related agent muraglitazar raised cardiovascular concerns (Nissen et al., 2005) — evidence about a different drug, not TTA itself.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence consists of one small placebo-controlled trial and three uncontrolled or dose-finding studies, none longer than 28 days and none measuring clinical events.

Medium 🟩 🟩

Improved Blood Lipid Profile ⚠️ Conflicted

At 1 g/day for 28 days, TTA lowered LDL (low-density lipoprotein, the main artery-clogging cholesterol carrier) in men with type 2 diabetes (Løvås et al., 2009), and cholesterol and triglycerides in a placebo-controlled psoriasis trial (Morken et al., 2011) and in HIV patients (Fredriksen et al., 2004). Healthy volunteers showed no lipid change after 7 days (Pettersen et al., 2008). Net reading: a modest effect is likely in people with abnormal lipids, but unproven in healthy adults with normal lipids.

Magnitude: LDL cholesterol fell from 4.2 to 3.7 mmol/L (about 12%) and the LDL/HDL (high-density lipoprotein, “good” cholesterol) ratio from 4.00 to 3.66 after 28 days in 16 men with type 2 diabetes; 18 healthy volunteers showed no significant change after 7 days.

Low 🟩

Lower Blood Pressure

In rats with kidney-artery-clip high blood pressure, TTA prevented and reduced hypertension and organ damage (Gudbrandsen et al., 2006). In people, blood pressure was only a secondary measure in the uncontrolled diabetes study (Løvås et al., 2009); Examine grades the human signal as a small improvement.

Magnitude: Blood pressure fell slightly in two small, short uncontrolled human studies (34 people, 7–28 days), graded as a small improvement on Examine’s TTA summary page, and TTA prevented and reduced surgically induced hypertension in rats; the published human reports give no blood-pressure outcome figure.

Better Blood-Sugar Control ⚠️ Conflicted

TTA prevented diet-induced insulin resistance in rats by boosting liver fat burning (Madsen et al., 2002). In one uncontrolled human study, 1 g/day for 28 days left glucose metabolism unchanged in diabetic men (Løvås et al., 2009). Net reading: the animal benefit is unconfirmed in humans.

Magnitude: No change in glucose metabolism after 28 days at 1 g/day in 16 men with type 2 diabetes, whereas rats were protected only under high-fat feeding or genetic obesity; the human report gives no glucose outcome figure beyond “not altered”.

Speculative 🟨

Lower Inflammatory Signaling

Small human studies found lower TNF-α, IL-8 and VCAM-1 (blood signals of inflammation and blood-vessel activation) (Fredriksen et al., 2004; Morken et al., 2011). These are unvalidated biomarkers; no clinical inflammatory outcome was measured.

Reduced Gut Inflammation

In rats with chemically induced colitis (inflammation of the large bowel), TTA lowered inflammatory messengers, oxidative damage and bowel-wall thickening but not overall disease activity (Bjørndal et al., 2013). The basis is animal-only.

Reduced Body Fat

In high-fat-fed rats, TTA shrank fat depots and weight gain despite higher food intake (Wensaas et al., 2009). No human body-composition study exists; the basis is animal-only.

Slower Artery Plaque Build-Up

In apoE-knockout mice (a strain bred to develop artery plaque), TTA reduced plaque and inflammatory messengers independently of cholesterol (Vik et al., 2013). No human plaque or event data exist.

Less Artery Re-Narrowing After Angioplasty

After balloon angioplasty (reopening a narrowed artery with a balloon catheter), TTA reduced re-narrowing in rabbits given it orally (Kuiper et al., 2001) and minipigs given it locally (Pettersen et al., 2001). Evidence is animal-only.

Better Heart Function After Heart Attack

In rats with heart failure after a heart attack, TTA improved heart function without changing heart remodeling (Øie et al., 2013). The basis is animal-only.

More Mitochondria

In rat liver cells, TTA increased mitochondrial number and respiratory capacity (Hagland et al., 2013), a trait linked to healthy aging. Evidence is animal and cell-based only.

Antioxidant Protection

TTA blocked LDL oxidation in the test tube (Muna et al., 1997) and reduced protein oxidation damage in rats fed for 50 weeks (Vigerust et al., 2012). Evidence is laboratory and animal only.

Anticancer Activity

TTA prolonged survival of rats with leukemia (Iversen et al., 2006) and slowed glioma (brain tumor) (Tronstad et al., 2001) and colon cancer cell growth (Lundemo et al., 2011). No human cancer study exists.

Stronger Bones

Rats given TTA for four months had higher thigh-bone mineral density and partly resisted bone loss after ovary removal (Stunes et al., 2011). No human bone data exist.

Extended Lifespan

No lifespan study of TTA in any mammal was found. Farmed salmon fed TTA survived a heart-muscle disease outbreak better (Alne et al., 2009), which does not show slowed aging.

Benefit-Modifying Factors

  • Genetic polymorphisms: The PPARA gene (which encodes PPARα) carries a common L162V variant reported to alter lipid responses to fibrates; whether it changes TTA response is untested.
  • Baseline lipid levels: Lipid reductions appeared in people with abnormal lipids (diabetes, HIV therapy, psoriasis) but not in healthy volunteers (Pettersen et al., 2008), so people with normal LDL and triglycerides can expect little lipid change.
  • Sex: The diabetes trial enrolled men only (Løvås et al., 2009) and most rodent work used males; no sex-stratified human data exist.
  • Pre-existing conditions: Type 2 diabetes, HIV-therapy-related lipid problems and psoriasis are the only studied conditions; in diabetic mice TTA protected the heart (Khalid et al., 2011), whereas in healthy mice it lowered heart efficiency (Hafstad et al., 2009).
  • Age: No trial targeted older adults; age-related declines in liver fat burning could plausibly increase response, but this is untested at the older end of the adult range.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no trial has reported a specific recurring adverse event, and human exposure totals a few dozen people treated for 28 days or less.

Medium 🟥 🟥

No risk reaches Medium: the only human safety data are small short-term studies reporting few mild events without event rates, and every specific risk below rests on biomarkers, animal work or related drugs.

Low 🟥

Mild Short-Term Adverse Events

TTA at 200–1,000 mg/day for 7 days caused few mild adverse events and no clinically significant laboratory changes in healthy volunteers (Pettersen et al., 2008); 1 g/day for 28 days was well tolerated in diabetic men (Løvås et al., 2009). No safety data extend beyond four weeks.

Magnitude: Not quantified in available studies. The published reports describe adverse events only as “few” and “mild” without per-group event rates, and no study lasted longer than 28 days.

Speculative 🟨

Lower Omega-3 Blood Levels

Two human trials found TTA lowered blood DHA (docosahexaenoic acid, a key omega-3 fat) (Løvås et al., 2009; Morken et al., 2011). This blood marker has no measured clinical consequence.

Reduced Heart Efficiency ⚠️ Conflicted

Healthy TTA-fed mice used more heart oxygen and recovered poorly from low blood flow (Hafstad et al., 2009); diabetic mice recovered better (Khalid et al., 2011). Net reading: effect varies by metabolic state; humans untested.

Liver Enlargement and Rodent Liver Tumors

TTA multiplies liver peroxisomes in rats (Aarsland & Berge, 1991), a trait linked to rodent liver tumors that primates largely resist (review by Klaunig et al., 2003). The basis is mechanistic.

Liver Fat Accumulation ⚠️ Conflicted

In high-fat-fed mice TTA raised liver triglycerides (Lundåsen et al., 2020), whereas in apoE-knockout mice it lowered them (Vik et al., 2013). Net reading: direction varies by animal model, and human liver fat is unmeasured.

Fibrate-Type Kidney, Muscle and Gallbladder Effects

Fibrates can raise creatinine (a kidney-function marker), injure muscle and promote gallstones. Short TTA trials showed no laboratory signal (Pettersen et al., 2008), so this concern rests on drug-class extrapolation only.

The PPARα/γ drug muraglitazar roughly doubled death, heart attack and stroke (Nissen et al., 2005). TTA acts weakly on PPARγ and lacks outcome data, so this is class extrapolation.

Growth-Signal Activation Counter to Longevity Goals

In rat liver cells, TTA activated mTOR (mechanistic target of rapamycin, a nutrient-sensing growth switch) and enlarged cells (Hagland et al., 2013). Many longevity strategies aim to dampen mTOR; human relevance is unknown.

Altered B-Vitamin Markers

Rats given TTA for 50 weeks had higher methylmalonic acid (a vitamin B12 status marker) (Lysne et al., 2016), possibly reflecting faster fat burning rather than true deficiency. Animal-only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been studied with TTA; PPARA gene variants such as L162V, which alter fibrate responses, could plausibly modify liver and lipid effects.
  • Baseline omega-3 status: People with a low omega-3 index (red-cell eicosapentaenoic acid, EPA, plus DHA) may be pushed lower by TTA’s omega-3-depleting effect.
  • Sex: Human safety data come mostly from men; female rats on antipsychotics gained more weight with TTA (Skrede et al., 2012), and pregnancy effects are unknown.
  • Pre-existing heart disease: Mouse data showing lower heart efficiency and poorer recovery after low blood flow (Hafstad et al., 2009) make ischemic heart disease (reduced heart blood flow) or heart failure the main theoretical risk setting.
  • Liver or kidney disease: TTA is cleared by liver oxidation and urinary excretion, so impairment may raise exposure; no studies included such patients.
  • Age: Older adults more often have reduced kidney function, heart disease and multiple medications, increasing interaction and class-effect risks; no trial targeted this group.

Key Interactions & Contraindications

  • Fibrates (fenofibrate, gemfibrozil, bezafibrate): Caution — overlapping PPARα activation may add liver and muscle strain without proven extra lipid benefit. Combined use is typically supervised, with ALT (alanine aminotransferase, a liver enzyme) and CK (creatine kinase, a muscle-damage marker) checks.
  • Statins (cholesterol-lowering drugs: atorvastatin, rosuvastatin, simvastatin): Monitor — additive LDL lowering is plausible, and fibrate-like agents raise statin muscle-injury risk. A CK check is the usual response to unexplained muscle pain or weakness.
  • Thiazolidinediones (PPARγ-activating diabetes drugs: pioglitazone, rosiglitazone): Caution — stacked PPAR activation resembles dual-agonist drugs that caused fluid retention and heart events. Weight gain, ankle swelling and breathlessness are the signs tracked.
  • Glucose-lowering drugs (metformin, insulin, sulfonylureas such as glipizide): Monitor — the human diabetes study found no glucose change (Løvås et al., 2009), so low-blood-sugar risk appears low; home glucose checks in the first weeks confirm this.
  • Antipsychotics (olanzapine, clozapine): Caution — in female rats TTA amplified antipsychotic weight gain (Skrede et al., 2012). Monthly weight and waist checks detect this.
  • HIV protease inhibitors (antiviral drugs: lopinavir, ritonavir): Monitor — TTA was combined with protease-inhibitor therapy for 4 weeks with lipid improvement (Fredriksen et al., 2004); longer-term interactions are unknown.
  • Tamoxifen: Monitor — in rats TTA prevented tamoxifen-induced fatty liver (Gudbrandsen et al., 2006), a possibly favorable interaction untested in humans; combined use involves the oncology team.
  • Over-the-counter niacin (nicotinic acid, vitamin B3 at lipid doses): Caution — additive lipid effects and additive liver strain. An ALT check after 4–6 weeks of combined use detects liver strain.
  • Over-the-counter orlistat (a fat-absorption blocker): Monitor — may reduce absorption of fatty acids including TTA, lowering its effect; separating TTA from orlistat-containing meals avoids this.
  • Common over-the-counter pain relievers (acetaminophen, ibuprofen): No interaction documented; routine monitoring suffices.
  • Fish oil (EPA, eicosapentaenoic acid, and DHA): Monitor, potentially favorable — rats showed additive cholesterol lowering and less oxidative damage (Vigerust et al., 2012); fish oil may offset TTA’s omega-3 depletion.
  • Oleoylethanolamide (a PPARα-activating supplement often stacked with TTA): Caution — additive PPARα activation with no combined safety data; not stacking, or ALT monitoring, limits this risk.
  • Red yeast rice and berberine (additive LDL-lowering supplements): Caution — additive lipid lowering; red yeast rice contains lovastatin-like compounds that add muscle risk. Lipid and CK checks track this.
  • L-carnitine: Monitor — TTA alters carnitine metabolism in rats (Bjørndal et al., 2013); clinical consequence unknown.
  • Ketogenic diet or prolonged fasting: Monitor — both raise liver fat burning and ketones, additive with TTA; fatigue or light-headedness are the signs to watch.
  • Heavy alcohol use: Caution — adds liver strain to a compound that remodels liver metabolism; low intake and ALT checks limit this.

Populations who should avoid Tetradecylthioacetic Acid:

  • Pregnant or breastfeeding women (no safety data)
  • Children and adolescents under 18 years
  • Active liver disease: Child-Pugh class B or C cirrhosis (moderate to severe liver failure), or ALT or AST (aspartate aminotransferase, a liver and muscle enzyme that leaks into blood when cells are damaged) above 3× the upper limit of normal
  • Severe kidney impairment: eGFR (estimated glomerular filtration rate, a kidney-filtering measure) below 30 mL/min/1.73 m²
  • Heart failure NYHA class III–IV (symptoms with minimal activity or at rest) or heart attack within the past 90 days
  • Symptomatic gallstone disease
  • People already taking two or more other PPAR-activating drugs or supplements (e.g., fenofibrate, pioglitazone, oleoylethanolamide)

Risk Mitigation Strategies

  • Baseline and 4–6-week labs: ALT, AST, creatinine/eGFR and CK measured before starting and after 4–6 weeks, with stopping if ALT exceeds 3× or CK 5× the upper limit, limit liver and muscle injury.
  • Omega-3 pairing: 1–2 g/day EPA plus DHA or two to three fatty-fish meals weekly counters TTA’s omega-3 depletion, with the omega-3 index typically rechecked at 3 months.
  • Dose within the studied range: Keeping to 1,000 mg/day or less avoids untested exposures, since no human data exist above this dose.
  • Time-limited courses: Courses of 4–8 weeks with reassessment keep exposure near the studied 28-day window, limiting unknown long-term liver and tumor risks.
  • Heart-disease precaution: People with heart disease can obtain cardiology review first and stop if breathlessness or reduced exercise tolerance appears, addressing the animal heart-efficiency signal.
  • No PPAR stacking: Not combining TTA with fibrates, thiazolidinediones or oleoylethanolamide avoids the fluid-retention and cardiovascular risks seen with multi-PPAR drugs.
  • Verified sourcing: A certificate of analysis showing ≥97% purity by HPLC (high-performance liquid chromatography) or NMR (nuclear magnetic resonance) limits contamination and mislabeling risk.
  • Weight tracking with antipsychotics: Monthly weight and waist checks catch the amplified weight gain seen in rats (Skrede et al., 2012).

Therapeutic Protocol

  • Clinical research protocol: 1,000 mg orally once daily for 28 days, used in the diabetes, HIV and psoriasis trials by Norwegian groups centered on Rolf Berge’s Bergen laboratory (Løvås et al., 2009).
  • Dose-finding range: 200, 600 and 1,000 mg/day were tested for 7 days in healthy volunteers; only 1,000 mg/day has efficacy data (Pettersen et al., 2008).
  • Supplement-market approach: Examine reports about 1 g daily in divided doses with meals, often combined with oleoylethanolamide for fat loss — an approach popularized by sports-nutrition vendors rather than clinical trials.
  • Established alternatives: Fenofibrate (prescription PPARα drug) and fish oil act on the same pathway with larger human datasets; they are alternatives with different evidence and access profiles, not defaults.
  • Time of day: No trial specified timing; taking TTA with a fat-containing meal mirrors normal fatty-acid absorption. Morning versus evening dosing is untested.
  • Half-life: Blood levels peak 2.5–4.5 hours after a dose (Pettersen et al., 2008); the terminal half-life is unreported, and incorporation into membrane fats suggests tissue persistence beyond blood levels.
  • Single versus split dose: Trials used one daily dose; splitting the dose (as Examine describes) may smooth blood levels but is untested.
  • Genetic factors: No pharmacogenetic dosing data exist; PPARA variant carriers have no specific dose guidance.
  • Sex: Dosing was identical by sex; women were underrepresented, so female-specific responses are unknown.
  • Age: No age-specific dosing exists; the 200–600 mg range has 7-day safety data (Pettersen et al., 2008) and is the lower-exposure option for older adults with reduced kidney function.
  • Baseline biomarkers: People with raised LDL or triglycerides showed lipid responses (Løvås et al., 2009); those with normal values showed none in 7 days (Pettersen et al., 2008).
  • Pre-existing conditions: Diabetes, HIV-therapy lipid problems and psoriasis have been studied; heart, liver and kidney disease have not, which argues for closer monitoring in those settings.

Discontinuation & Cycling

  • Short-term, not lifelong: Human use is documented only for up to 28 days; lifelong use has no safety data.
  • Withdrawal effects: None reported; lipid changes are expected to return toward baseline after stopping.
  • Tapering: Not required pharmacologically; no rebound effect has been documented.
  • Cycling: No human data; in rats the lipid effect persisted with longer use (Asiedu et al., 1996), so cycling serves to limit exposure rather than maintain efficacy.
  • Stop triggers: ALT above 3× the upper limit, CK above 5×, new breathlessness, planned pregnancy or unexplained weight gain.

Sourcing and Quality

  • No pharmaceutical-grade product: TTA is not an approved drug; it is sold as a research chemical (e.g., Sigma-Aldrich, Santa Cruz Biotechnology, labeled for research use only) or as scarce supplement powders and capsules.
  • What to look for: A batch-specific certificate of analysis with identity (NMR or mass spectrometry), purity ≥97%, residual-solvent and heavy-metal results from an independent lab.
  • Third-party testing: ConsumerLab has not tested TTA, and no USP (United States Pharmacopeia) or NSF (NSF International, a product-certification body) certification exists for TTA products, so independent verification depends on per-batch lab testing.
  • Formulation: Trials used the free acid; an ethyl-ester form was absorbed and distributed like the free acid in rats (Gudbrandsen et al., 2009), while supplement blends combining TTA with oleoylethanolamide have no safety data.
  • Reputable suppliers: Research-chemical suppliers publish purity specifications but do not intend products for human use; no supplement brand has independently verified TTA content.

Practical Considerations

  • Time to effect: Lipid changes appeared after 4 weeks at 1 g/day (Løvås et al., 2009); 7 days was too short to show any change (Pettersen et al., 2008).
  • Common pitfalls: Assuming rodent fat-loss results translate to humans, stacking several PPAR activators, exceeding 1 g/day, ignoring the omega-3 decline, and buying powders without batch testing.
  • Regulatory status: Not approved as a drug by the FDA (U.S. Food and Drug Administration), the European Medicines Agency or Norwegian authorities; its status as a dietary ingredient is unestablished, and most sources sell it for research use only.
  • Cost and accessibility: Research-grade TTA is sold in small quantities to laboratories, and consumer supplements are intermittently available, making reliable access difficult.
  • Research incentives: Payers have no reason to fund TTA trials because inexpensive generic statins and fibrates exist, and without a strong commercial sponsor large trials are unlikely — a structural bias that keeps the evidence gap open.

Interaction with Foundational Habits

  • Sleep: None known — no study has measured sleep with TTA. Any indirect benefit would depend on metabolic improvements that are unproven in humans; timing a dose with the evening meal has no known sleep effect.
  • Nutrition: Potentiating and depleting — effects were largest with high-fat diets in rodents, and TTA lowers blood omega-3 fats. Including fatty fish two to three times weekly and taking TTA with a fat-containing meal are practical considerations.
  • Exercise: Potentially potentiating — TTA increases fat burning in human muscle cells through PPARδ (Løvås et al., 2009), overlapping with endurance-training adaptations, but no human performance study exists; the healthy-mouse heart-efficiency signal (Hafstad et al., 2009) suggests caution with maximal-intensity training.
  • Stress management: Indirect — in liver cells, stress-hormone analogs (dexamethasone) amplified and insulin blunted TTA’s enzyme induction (review by Skrede et al., 1997); human cortisol effects are unstudied.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes a reference point: a fasting lipid panel with ApoB (apolipoprotein B, a count of harmful particles), liver enzymes, kidney function, CK, fasting glucose with HbA1c (a three-month blood-sugar average), hs-CRP (high-sensitivity C-reactive protein, an inflammation marker) and an omega-3 index, all drawn after a 10–12-hour fast. Because TTA is unapproved and human data stop at 28 days, the liver, kidney and muscle tests serve as safety checks as much as efficacy markers.

Ongoing monitoring follows a cadence of 4–6 weeks after starting, then every 3 months while use continues, and once 4–8 weeks after stopping. Success is a meaningful fall in LDL, ApoB or triglycerides from the individual’s own baseline without rises in ALT, CK or creatinine and without a drop in the omega-3 index; if lipids have not moved by 8 weeks, the compound is unlikely to help that person.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol <100 mg/dL (<2.6 mmol/L) Main efficacy marker Fasting; conventional target <130 mg/dL; pair with ApoB
ApoB <80 mg/dL Counts artery-clogging particles ApoB = apolipoprotein B, the protein on each harmful lipoprotein particle; conventional up to ~100–130 mg/dL
Triglycerides <100 mg/dL (<1.1 mmol/L) Efficacy marker 10–12-hour fast; conventional normal <150 mg/dL
HDL cholesterol ≥50 mg/dL Lipid balance Trials showed rises in HDL proteins; conventional ≥40 mg/dL (men), ≥50 mg/dL (women)
ALT / AST ALT <25 U/L; AST <25 U/L Liver safety Conventional upper limit ~40–55 U/L; stop threshold >3× upper limit; hard exercise in the prior 48 h can raise values
Creatinine / eGFR eGFR >90 mL/min/1.73 m² Kidney safety Fibrate-type creatinine rises are possible; conventional eGFR ≥60 considered adequate
CK No established functional target; track change from own baseline Muscle safety CK = creatine kinase; strenuous exercise in the prior 48 h raises values; stop threshold >5× upper limit
Omega-3 index ≥8% Tracks omega-3 depletion Red-cell EPA plus DHA; conventional labs rarely report a range; typical Western values 4–6%
Fasting glucose / HbA1c 70–90 mg/dL; HbA1c <5.4% Metabolic effect HbA1c = glycated hemoglobin; conventional normal glucose <100 mg/dL and HbA1c <5.7%
hs-CRP <1.0 mg/L Systemic inflammation hs-CRP = high-sensitivity C-reactive protein; repeat if >3 mg/L during infection; conventional <3 mg/L
Methylmalonic acid <0.27 µmol/L B12 status check May rise from faster fat burning, per rat data; pair with serum B12; conventional upper limit ~0.3–0.4 µmol/L depending on lab

Qualitative markers:

  • Energy levels and exercise tolerance, especially any new breathlessness
  • Digestive comfort after dosing
  • Waist circumference and body weight trend
  • Muscle aches or weakness
  • Skin changes in people with psoriasis

Emerging Research

  • No active human trials: A ClinicalTrials.gov search on 26 September 2026 found no ongoing TTA trials; the only registered study is the completed phase 2 diabetes trial NCT00605787 (16 men, 1 g/day for 28 days, lipid and glucose endpoints).
  • Omega-3 interplay: Long-term rat work found fish oil and TTA additive for cholesterol lowering but opposite for oxidative damage (Vigerust et al., 2012); a human trial of the combination could resolve TTA’s omega-3 depletion concern.
  • Cardiac safety: Opposite heart effects in healthy versus diabetic mice (Hafstad et al., 2009; Khalid et al., 2011) mean human cardiac imaging studies could weaken or strengthen the case for health-focused users.
  • Biomarkers of liver fat burning: Plasma 3-hydroxyisobutyrate and methylmalonic acid tracked TTA-induced liver fat burning in rats (Bjune et al., 2021), potentially offering simple blood tests to confirm individual response.
  • HDL remodeling: In mice TTA shifted cholesterol toward large HDL particles (Lundåsen et al., 2020); whether this occurs in humans and affects artery health is unknown.
  • Growth signaling and longevity: TTA’s activation of mTOR in rat liver cells (Hagland et al., 2013) could weaken its longevity case if confirmed in human tissue, given that mTOR suppression extends lifespan in animals.
  • Lifespan gap: No mammalian lifespan study of TTA was found; a rodent lifespan study would directly test whether its metabolic effects translate into longer healthy life.

Conclusion

Tetradecylthioacetic acid is a synthetic fatty acid that cannot be burned for energy but pushes the liver and muscles to burn more ordinary fat. For health-focused adults, its appeal rests on laboratory findings: lower blood fats, less body fat, less artery plaque, calmer inflammation and more cellular power plants in rodents.

The human picture is much thinner. A few small, short studies in people with diabetes, blood-fat problems from virus treatment, or a skin disease suggest a modest drop in harmful cholesterol and blood fats over about a month, while healthy volunteers showed no change in a week. No human study has shown better blood sugar, fat loss, heart outcomes or longer life, and no lifespan study exists in any mammal.

Short-term use appeared well tolerated, but safety knowledge ends at four weeks. The open questions are real: lower omega-3 levels in human blood, reduced heart efficiency in healthy mice, liver changes typical of this drug family in rodents, heart harm with a related drug, and activation of a growth pathway that many longevity strategies try to calm.

The evidence base is also narrow in origin: most studies come from one Norwegian research network whose lead scientists have been reported as shareholders in the company developing the compound. Overall, it remains an experimental agent with a plausible mechanism, modest short-term human blood-fat signals and a long-term risk profile that is largely unknown.

Top - Benefits - Risks - Protocol